tiprankstipranks
Fate Therapeutics prices 14.5M shares at $5.50 in underwritten offering
PremiumThe FlyFate Therapeutics prices 14.5M shares at $5.50 in underwritten offering
1M ago
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2M ago
Fate Therapeutics to Present at Upcoming March Investor Conferences
PremiumPress Releases
Fate Therapeutics to Present at Upcoming March Investor Conferences
2M ago
Fate Therapeutics reports Q4 EPS (45c), consensus (52c)
PremiumThe FlyFate Therapeutics reports Q4 EPS (45c), consensus (52c)
2M ago
Fate Therapeutics Inc (FATE) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Fate Therapeutics Inc (FATE) Q4 Earnings Cheat Sheet
2M ago
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
PremiumPress Releases
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
2M ago
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress ReleasesFate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4M ago
Fate Therapeutics price target lowered to $8 from $12 at Mizuho
PremiumThe Fly
Fate Therapeutics price target lowered to $8 from $12 at Mizuho
5M ago
Fate Therapeutics price target lowered to $4.50 from $5 at Stifel
PremiumThe Fly
Fate Therapeutics price target lowered to $4.50 from $5 at Stifel
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100